Adrienne Monson – Lifestyle
Author:
Vanotech Ltd
Chengdu Origen and Vanotech Announce KHN921 Investigational New Drug application clearance by the US FDA for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations
May 13, 2026